Ovarian Cancer Trial, Recruiting NCT07532434 Sponsor: Peking University Third Hospital Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT07532434
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women aged 18 or older at the time of joining the trial
  • People who have been confirmed through genetic testing to carry a harmful or likely harmful change in a gene linked to high risk of ovarian cancer (such as BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, or PALB2)
  • People who are willing to give their consent to participate and allow the trial team to access their medical records, genetic test results, and follow-up health information
  • People who are able to complete questionnaires about quality of life, mental wellbeing, and related topics

Who may not be able to join:

  • People who have previously been diagnosed with ovarian cancer, fallopian tube cancer, or a related cancer of the abdominal lining (called primary peritoneal cancer)
  • People who currently have another serious or advanced-stage cancer diagnosis
  • People for whom regular long-term follow-up over 3 years would not be possible due to significant psychological, social, or geographic reasons
  • People who have had major prior surgery in the pelvic area that would make a keyhole (laparoscopic) preventive surgery on the ovaries or fallopian tubes not feasible

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 18610689868

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University Third Hospital
Registry
ClinicalTrials.gov
Start date
30 September 2025
Est. completion
30 September 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Ovarian Cancer

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov